Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results

Hepatology Research

Volumn 46, Issue 3, 2016, Pages E60-E69

  Ogawa, Masahiro ^a   Takayasu, Kentaro ^a   Hirayama, Midori ^a   Miura, Takao ^a   Shiozawa, Katsuhiko ^a   Abe, Masahisa ^a   Matsumoto, Naoki ^a   Nakagawara, Hiroshi ^a   Ohshiro, Shu ^a   Yamamoto, Toshiki ^a   Tanaka, Naohide ^a   Moriyama, Mitsuhiko ^a   Mutou, Haruomi ^a   Yamamoto, Yoshinobu ^b   Irie, Toshiyuki ^c  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Takenotsuka Health Center   (Japan)

^c Hitachi General Hospital   (Japan)

Author keywords

Balloon occlusion; Balloon occluded transarterial chemoembolization; Conventional microcatheter transcatheter arterial chemoembolization; Embolization; Hepatocellular carcinoma; Miriplatin

Indexed keywords

GELATIN; MIRIPLATIN;

ADULT; AGED; ARTICLE; BALLOON CATHETER; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84937801022     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12527     Document Type: Article

References (39)

1. Hanada M, Baba A, Tsutsumishita Y etal. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 2009; 100: 189.
2. Hanada M, Baba A, Tsutsumishita Y etal. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat live by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009; 64: 473-83.
3. Kishimoto S, Noguchi T, Yamaoka T etal. In vitro release of SM-11355, cis[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)] platinum(II) suspended in lipiodol. Biol Pharm Bull 2000; 23: 637-40.
4. Okusaka T, Okada S, Nakanishi T etal. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-76.
5. Okusaka T, Kasugai H, Ishii H etal. A randomized phase II trial of intra-arterial chemotherapy using SM-11355(Miriplatin)for hepatocellular carcinoma. PHASE II STUDIES Invest New Drugs 2012; 30: 2015-25.
6. th Edition.2008;
7. Common Terminology Criteria for Adverse Events v4.0 (CTCAE).2009;
8. Nikhil B, Amesur A, Albert B etal. Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig Dis Sci 2008; 53: 1400-4.
9. Maurizio Grosso A, Claudio Vignali A, Pietro Quaretti A etal. Chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: Preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31: 1141-9.
10. Seki A, Hori S, Kobayashi K etal. Transcatheter Arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: Single-Center Experience. Cardiovasc Intervent Radiol 2011; 34: 557-65.
11. Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin: Salvage transcatheter arterial chemoembolization with drug-eluting microspheres for Unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2012; 35: 555-62.
12. Osuga K, Maeda N, Higashihara H etal. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol 2012; 17: 306-15.
13. Andrew LLM, Victoria G, Simon WL etal. Doxorubicin eluting beads-1: Effects of drugs loading on bead characteristics and drug distribution. J Mater Sci 2007; 18: 1691-9.
14. Andrew LLM, Victoria G, Andrew WL etal. DC Beads: In vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Intev Radiol 2006; 17: 335-42.
15. Grüntzig A, Hopff H. Perkutane rekanalisation chronischer arterieller verschlüsse mit einem neuen Dilatationskatheter. Dtsch Med Wochenschr 1974; 99: 2502-5.
16. Kanagawa H, Mima S, Kouyama H etal. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996; 11: 51-8.
17. Nakamura H, Tanaka M, Oi H etal. Hepatic artery embolization using balloon catheters. Rinsho Hoshasen 1985; 30: 469-73.
18. Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 2013; 36: 706-13.
19. Irie T, Kuramochi M, Takahashi N. Study of blood pressure changes in the artery embolization: A Study on the reason for enhanced Lipiodol integrated action in the micro-balloon occlusion under TACE. Jpn J Intervent Radiol 2011; 26: 49-54.
20. Okabe K, Beppu T, Haraoka K etal. Safety and Short-term Therapeutic Effects of Miriplatin-Lipiodol Suspension in Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma. Anticancer Res 2011; 31: 2983-8.
21. Ikeda K, Okusaka T, Ikeda M etal. Transcatheter arterial chemo embolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)-safety and efficacy in combination with embolizing agents. Gan To Kagaku Ryoho 2010; 37: 271-5.
22. Imai Y, Chikayama T, Nakazawa M et al. Usefulness of miriplatin as an anticancer agent for transcatherter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 2012; 47: 179-86.
23. Imai N, Ikeda K, Kawamura Kawamura Y etal. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clinical Oncology 2012; 42: 175-82.
24. Kaneko S, Furuse J, Kudo M etal. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular carcinoma 2010 update. Hepatology Res 2012; 42: 523-42.
25. Okabe K, Beppu T, Haraoka K, etal. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res 2011; 31: 2983-8.
26. Kora S, Urakawa H, Mitsufuji T etal. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc Intervent Radiol 2013; 36: 1023-9.
27. Kora S, Urakawa H, Mitsufuji T etal. Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. Hepatology Res 2013; 43: 1100-4.
28. Seko Y, Ikeda K, Kawamura Y etal. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatology Res 2013; 43: 942-9.
29. Inoue T, Kudo M, Hatanaka K etal. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: Comparison with dynamic CT. Oncology 2013; 84: 51-7.
30. Xia Y, Kudo M, Minami Y etal. Response Evaluation of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas: The Usefulness of Sonazoid-Enhanced Harmonic Sonography. Oncology 2008; 75: 99-105.
31. Morimoto M, Shirato K, Sugimori K etal. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 65-9.
32. Numata K, Tanaka K, Kiba T etal. Using contrast-enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. AJR Am J Roentgenol 2001; 176: 1199-205.
33. Minami Y, Kudo M, Kawasaki T etal. Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 180: 703-8.
34. Kudo M, Hatanaka K, Maekawa K. Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008; 16: 130-9.
35. Tanaka S, Misu K, Fukuda J etal. Characterization of Liver Tumors with Contrast-enhanced US using Sonazoid-Actual experience of contrast-enhanced US using EUB-8500-. MEDIX 2008; 47: 22-6.
36. Matsumoto T, Endo J, Hashida K etal. Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations. Minim Invasive Ther 2014; 29: 1-7.
37. Fujiyama S, Shibata J, Maeda S etal. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Cancer Research UK British Journal of Cancer 2003; 89: 1614-9.
38. Okusaka T, Okada S, Nakanishi T etal. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Kluwer Academic Publishers. Manufactured in the United States. Invest New Drugs 2004; 22: 169-76.
39. Kamimura K, Suda T, Tamura Y et al. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BioMed Central The Open Access Publisher. BMC Gastroenterol 2012; 12: 127.